332 related articles for article (PubMed ID: 21229642)
81. Glioblastoma cell line-derived spheres in serum‑containing medium versus serum-free medium: a comparison of cancer stem cell properties.
Hong X; Chedid K; Kalkanis SN
Int J Oncol; 2012 Nov; 41(5):1693-700. PubMed ID: 22922964
[TBL] [Abstract][Full Text] [Related]
82. Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells.
Vengoji R; Ponnusamy MP; Rachagani S; Mahapatra S; Batra SK; Shonka N; Macha MA
Carcinogenesis; 2019 Mar; 40(1):2-14. PubMed ID: 30475990
[TBL] [Abstract][Full Text] [Related]
83. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.
Liang J; Piao Y; Henry V; Tiao N; de Groot JF
Oncotarget; 2015 Oct; 6(31):31479-92. PubMed ID: 26362401
[TBL] [Abstract][Full Text] [Related]
84. Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
Mansour J; Fields B; Macomson S; Rixe O
Target Oncol; 2014 Dec; 9(4):395-8. PubMed ID: 24998223
[TBL] [Abstract][Full Text] [Related]
85. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo.
Denicolaï E; Baeza-Kallee N; Tchoghandjian A; Carré M; Colin C; Jiglaire CJ; Mercurio S; Beclin C; Figarella-Branger D
Oncotarget; 2014 Nov; 5(21):10934-48. PubMed ID: 25400117
[TBL] [Abstract][Full Text] [Related]
86. A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
Johansson F; Ekman S; Blomquist E; Henriksson R; Bergström S; Bergqvist M
Anticancer Res; 2012 Sep; 32(9):4001-6. PubMed ID: 22993350
[TBL] [Abstract][Full Text] [Related]
87. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
[TBL] [Abstract][Full Text] [Related]
88. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
[TBL] [Abstract][Full Text] [Related]
89. RAD18 mediates resistance to ionizing radiation in human glioma cells.
Xie C; Wang H; Cheng H; Li J; Wang Z; Yue W
Biochem Biophys Res Commun; 2014 Feb; 445(1):263-8. PubMed ID: 24518219
[TBL] [Abstract][Full Text] [Related]
90. Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma.
Li N; Maly DJ; Chanthery YH; Sirkis DW; Nakamura JL; Berger MS; James CD; Shokat KM; Weiss WA; Persson AI
Mol Cancer Ther; 2015 Feb; 14(2):419-28. PubMed ID: 25522764
[TBL] [Abstract][Full Text] [Related]
91. Effects of the Combined Treatment with a G-Quadruplex-Stabilizing Ligand and Photon Beams on Glioblastoma Stem-like Cells: A Magnetic Resonance Study.
Palma A; Grande S; Luciani AM; Ricci-Vitiani L; Buccarelli M; Pallini R; Triveri A; Pirota V; Doria F; D'Alessandris QG; Berardinelli F; Antoccia A; Rosi A
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884511
[TBL] [Abstract][Full Text] [Related]
92. Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
Riedel M; Struve N; Müller-Goebel J; Köcher S; Petersen C; Dikomey E; Rothkamm K; Kriegs M
Oncotarget; 2016 Sep; 7(38):61988-61995. PubMed ID: 27542273
[TBL] [Abstract][Full Text] [Related]
93. Combination treatment for glioblastoma with temozolomide, DFMO and radiation.
Alexiou GA; Vartholomatos E; I Tsamis K; Peponi E; Markopoulos G; A Papathanasopoulou V; Tasiou I; Ragos V; Tsekeris P; Kyritsis AP; Galani V
J BUON; 2019; 24(1):397-404. PubMed ID: 30941997
[TBL] [Abstract][Full Text] [Related]
94. A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers.
Shiras A; Bhosale A; Shepal V; Shukla R; Baburao VS; Prabhakara K; Shastry P
Neoplasia; 2003; 5(6):520-32. PubMed ID: 14965445
[TBL] [Abstract][Full Text] [Related]
95. Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin.
Jiang Y; Marinescu VD; Xie Y; Jarvius M; Maturi NP; Haglund C; Olofsson S; Lindberg N; Olofsson T; Leijonmarck C; Hesselager G; Alafuzoff I; Fryknäs M; Larsson R; Nelander S; Uhrbom L
Cell Rep; 2017 Jan; 18(4):977-990. PubMed ID: 28122246
[TBL] [Abstract][Full Text] [Related]
96. Tumour cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy.
Tong L; Yi L; Liu P; Abeysekera IR; Hai L; Li T; Tao Z; Ma H; Xie Y; Huang Y; Yu S; Li J; Yuan F; Yang X
Oncol Rep; 2018 Jul; 40(1):463-471. PubMed ID: 29749548
[TBL] [Abstract][Full Text] [Related]
97. Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Berger G; Grauwet K; Zhang H; Hussey AM; Nowicki MO; Wang DI; Chiocca EA; Lawler SE; Lippard SJ
Cancer Lett; 2018 Mar; 416():138-148. PubMed ID: 29246647
[TBL] [Abstract][Full Text] [Related]
98. Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
Inada M; Sato A; Shindo M; Yamamoto Y; Akasaki Y; Ichimura K; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6743-6750. PubMed ID: 31810939
[TBL] [Abstract][Full Text] [Related]
99. Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
Fleurence J; Bahri M; Fougeray S; Faraj S; Vermeulen S; Pinault E; Geraldo F; Oliver L; Véziers J; Marquet P; Rabé M; Gratas C; Vallette F; Pecqueur C; Paris F; Birklé S
Int J Cancer; 2020 Jan; 146(2):424-438. PubMed ID: 31241171
[TBL] [Abstract][Full Text] [Related]
100. CD44-associated radioresistance of glioblastoma in irradiated brain areas with optimal tumor coverage.
Liu WH; Lin JC; Chou YC; Li MH; Tsai JT
Cancer Med; 2020 Jan; 9(1):350-360. PubMed ID: 31746135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
